Welcome to our dedicated page for Tempest Therapeutics news (Ticker: TPST), a resource for investors and traders seeking the latest updates and insights on Tempest Therapeutics stock.
Tempest Therapeutics, Inc. develops clinical-stage cell therapy and small-molecule product candidates for cancer and related disease areas. News about TPST centers on its dual-targeting CAR-T platform, including TPST-2003, a CD19/BCMA CAR-T therapy under development for relapsed or refractory multiple myeloma, and clinical updates from programs such as REDEEM-1 and POEMS-1.
Company updates also cover CAR-T manufacturing and technology-transfer work, partner-supported development activities, business development and licensing priorities, and the amezalpat small-molecule program. Recurring corporate news includes financial results, pipeline portfolio changes following acquired CAR-T assets, leadership appointments, and governance or capital-structure matters tied to the company’s Nasdaq-listed common stock.
Tempest Therapeutics (Nasdaq: TPST) announced the appointment of Dr. Ronit Simantov to its board of directors, enhancing its leadership in oncology. Dr. Simantov brings over 20 years of experience from roles at Gamida Cell and Pfizer, where she led significant oncology programs. CEO Steve Brady expressed enthusiasm for her insights as Tempest advances its clinical programs, especially with its candidate therapies TPST-1495 and TPST-1120. This appointment aims to strengthen the company’s position in the competitive oncology landscape and expand its strategic oversight.
Tempest Therapeutics (Nasdaq: TPST) announced that Dr. Sam Whiting, the chief medical officer, will join a panel titled “Developing Therapies for the Next Immuno-Oncology Targets” at the William Blair 2021 Biotech Focus Conference on July 14, 2021, at 2:10 p.m. ET. Tempest is advancing clinical programs TPST-1495 and TPST-1120, which target EP2/EP4 and PPARα, respectively, through Phase 1 studies. The company aims to develop innovative therapies combining targeted and immune-mediated mechanisms to treat various tumors. More details are available on their investor website.
Tempest Therapeutics (Nasdaq: TPST) has appointed Christine Pellizzari, a 20-year industry veteran, to its Board of Directors. CEO Steve Brady emphasized the importance of her broad experience in supporting the company’s growth and advancing its oncology pipeline. Pellizzari, currently the chief legal officer at Insmed, has a strong background in legal and regulatory affairs, having overseen successful IPOs and compliance infrastructure in previous roles. Tempest continues to develop its promising clinical programs, TPST-1495 and TPST-1120, which are in Phase 1 studies for cancer treatment.
Tempest Therapeutics, Inc. (NASDAQ: TPST) announced the successful merger with Millendo Therapeutics, effective June 28, 2021. The merger facilitated a $30 million PIPE financing from notable healthcare investors, providing essential funds for advancing Tempest's clinical programs, including TPST-1495 and TPST-1120 through Phase 1 studies. Following the merger, a 1:15 reverse stock split was executed, resulting in approximately 6.7 million shares outstanding. Important board updates were made, positioning Tempest for future growth as it aims to deliver innovative cancer therapies.